Stay updated with breaking news from Severe Plaque. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tremfya demonstrated greater treatment persistence than interleukin-17 inhibitors in patients with moderate to severe plaque psoriasis and achieved clinical efficacy in scalp psoriasis, according to data presented here.Tremfya (guselkumab, Janssen Biotech) is the first and only fully human selective interleukin (IL)-23 approved in the United States for adults with moderate to severe plaque
- Seven posters will include clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and atopic dermatitis (AD), including data from the successful pediatric maximum usage study
- Five posters will highlight clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and for atopic dermatitis in patients as young as two - Dermavant Sciences, a biopharmaceutical
- Two posters will highlight clinical data for VTAMA cream on treat-to-target outcomes and quality of life measures - Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing
How Embark® App combines a medical and digital approach to support patients in managing their Enbrel® (etanercept) treatment.